RxDoctor Payments Data

Cheryl Stone

Physician Assistant · Oklahoma City, OKNPI 1457348245

Payments from drug & device makers

$2,803in general payments, 2019–2025

Across 145 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$924
  • Boehringer Ingelheim$608
  • Novartis$432
  • Regeneron Healthcare Solutions, Inc.$209
  • Novo Nordisk$186
  • E.r. Squibb & Sons, L.L.C.$70
  • plus $375 from 11 others

What the payments were for

  • Food & beverage$2,803100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,803 in reported general payments places this provider in the 85th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$62,754
Medicare patients
585
Services billed
851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab640$568,228
Praluent PenAlirocumab159$144,072
JardianceEmpagliflozin85$103,312
TrulicityDulaglutide73$85,771
OzempicSemaglutide68$70,044
MounjaroTirzepatide45$57,977
FarxigaDapagliflozin Propanediol51$46,805
Repatha SyringeEvolocumab45$35,355
VascepaIcosapent Ethyl24$20,324
EliquisApixaban25$19,331
Ezetimibe303$9,043
NexlizetBempedoic Acid/Ezetimibe13$7,173
Rosuvastatin Calcium351$6,131
Atorvastatin Calcium254$2,795
Colesevelam Hcl26$2,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$608$103,31285 claims
Novo NordiskOzempic$186$70,04468 claims
AstraZenecaFarxiga$48$46,80551 claims
PfizerEliquis$14$19,33125 claims
Esperion Therapeutics, Inc.Nexlizet$20$7,17313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →